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Evaluating unspecific oxidative stress parameters  
in the sera of patients with irritable bowel syndrome
abstract
Objective: Irritable bowel syndrome (IBS) is a common global condition 
characterized by abdominal pain and alterations in bowel habits not caused 
by other organic diseases and its etiopathogenesis has not been elucidated. In 
this study, we aimed to evaluate the oxidative stress parameters in patients 
with IBS.
Materials and methods: Fifty patients diagnosed with IBS using the 
Rome III criteria and a control group of 50 healthy subjects were included 
in the study. Oxidative stress parameters including total oxidant status 
(TOS), total antioxidant status (TAS) and oxidative stress index (OSI) 
values were analyzed from all study subjects.
Results: Compared to the controls; the TOS and OSI values were sig-
nificantly higher, and the TAS value was significantly lower in IBS patients 
(p < 0.001 for all).
Conclusions: In present study we demonstrated that oxidative stress 
increased and antioxidant capacity decreased in IBS, and antioxidants 
might be beneficial in the supportive treatment for IBS.
 
IntroductIon
Irritable bowel syndrome (IBS) is a common global condition that impairs quality of life. It is characterized by abdominal pain and al-
tered bowel habits not caused by other known organic diseases. Ab-
dominal pain in IBS is usually described as a crampy sensation with 
variable intensity and periodic exacerbations. The location and character 
of the pain can vary widely. Emotional stress and eating may exacerbate 
the pain, while defecation often provides some relief (1, 2). Altered 
bowel habits are ranging from diarrhea and constipation or normal 
bowel habits alternating with either diarrhea and/or constipation. Con-
stipation may last from days to months, with interludes of diarrhea or 
normal bowel function. Stools are often hard and patients may also 
experience a sense of incomplete evacuation even when the rectum is 
empty. Diarrhea is usually occurs during waking hours, most often in 
the morning or after meals and accompanied by lower abdominal 
cramps and urgency. Stools generally characterized as frequent loose 
stools of small to moderate volume with mucus discharging. Numerous 
factors have been implicated in the etiology of IBS, including genetics, 
intestinal infections, over-production of intestinal bacteria, increased 
cytokine response and inflammation, irregularity of serotonergic func-
tions, and psychosocial aspects (3–8). Since it has been regarded as a 
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been fully illuminated, diagnosis of IBS is made based on 
the Rome III clinical criteria, last modified in 2006 (9).
The term oxidative stress is used to describe a series of 
chemical reactions that result in the production of free 
oxygen radicals and other reactive molecules (10). These 
free radicals and reactive oxygen molecules are neutral-
ized by the complex structure of the antioxidant system 
but when the pro-oxidant and antioxidants systems are 
dysregulated, oxidative stress can damage important cel-
lular components including lipids, proteins and nucleic 
acids (11, 12). It was already showed that the oxidative 
stress products increase if there is an endocrine disease 
that affects the body’s metabolic rate and an inflamma-
tory disease which cause acute or chronic organ damage 
in previous studies (13-17). But there is limited number 
of studies investigating the presence of oxidative stress in 
non organic and functional diseases. Therefore the cur-
rent study was undertaken and aimed to evaluate the role 
of oxidative stress in IBS etiopathogenesis by measuring 
the total oxidative status (TOS), total antioxidant status 
(TAS) values and calculating oxidative stress index (OSI) 
by Erel’s method which is easy, stable, reliable, sensitive, 
inexpensive and fully automated in IBS patients.
materIals and methods
The study participants included 50 patients who pre-
sented at the Gastroenterology Polyclinic of Harran Uni-
versity Medical Faculty and were diagnosed with IBS, and 
a control group of 50 healthy individuals. The diagnosis 
of IBS was made according to the Rome III criteria9. 
Routine laboratory studies (complete blood count, fasting 
blood glucose, urea, creatinine, alanine amino transferase, 
aspartate amino transferase, alkaline phosphatase, gama 
glutamil transferase, sedimentation, C- reactive protein, 
thyroid stimulating hormone) and abdominal ultrasono-
graphic examination were evaluated while selection of 
patients to exclude from the other diseases. Patients < 18 
years old, addicted to alcohol or medication, and those 
with a previous diagnosis of hematological, renal, hepatic, 
cardiovascular, neurological, chroninc inflammatory 
bowel disease, chronic inflammatory connective tissue 
diseases and malign diseases were excluded from the 
study. Informed consent, conforming to the Helsinki 
Declaration of 2008, was obtained from all patients and 
control subjects. The local ethics committee approved the 
study protocol.
Biochemical analysis
All blood samples were drawn from a large antecubital 
vein without interruption of venous flow, following an 
overnight fasting state into blood tubes and immediately 
stored on ice at 4 °C. The serum was then separated from 
the cells by centrifugation at 3000 rpm for 10 min and 
they were stored until analyzing at –80 °C. Ten milliliters 
of blood was used for baseline routine laboratory tests. 
Thyroid stimulatin hormone (TSH), levels were analyzed 
using an electrochemiluminescence immunometric assay 
Table 1: Baseline comparison of the demographic, laboratory and clinical characteristics of all subjects
Parameters IBS Group (n=50) Healthy subjects (n=50)  p
Age (years) 37.2±11.9 39.5±11.7  0.932
Sex (male/female) 27/23 28/22  0.989
Hematocrit (%) 41.0±4.6 41.7±4.3  0.646
Glucose (mg/dL) 99.2±7.1 93.9±4.3  0.277
Urea (mmol/L) 28.5±8.9 28.0±10.8  0.587
Creatinine (mg/dL) 0.6±0.1 0.7±0.1  0.534
AST (U/L) 24.3±11.6 23.9±14.2  0.219
ALT (U/L) 27.5±19.4 29.4±25.3  0.761
TSH (mIU/L) 2.7±0.7 2.5±0.8  0.511
Abbreviations: IBS: Irritable Bowel Syndrome, AST: aspartate aminotransferase, ALT: alanine aminotransferase, TSH: Thyroid stimulating hormone
Table 2: Mean ± SD of TAS, TOS and OSI levels
Parameters  IBS Group (n=50) Healthy subjects (n=50)  p
TAS (μmol Trolox equivalent/L) 850 ± 80.0 1040 ± 90.0  <0.001
TOS (μmol H2O2 equivalent/L) 44.84±1.56  37.87±1.11  <0.001
OSI (arbitrary units) 5.27±0.48 3.64±0.26  <0.001 
Abbreviations: IBS: Irritable Bowel Syndrome, TAS: Total Antioxidant Status, TOS: Total Oxidant Status, OSI: Oxidative Stress Index
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(ECLIA) method with a Roche Elecsys E170 immuno-
analyzer (Roche Diagnostics, Burgess Hill, UK). Serum 
urea, creatinine (Crea), fasting blood glucose (FBG), as-
partate aminotransferase (AST), alanine aminotransfer-
ase (ALT), were determined using commercially available 
assay kits (Abbott®, Abbott Park, North Chicago, Illinois, 
USA) with an auto-analyzer (Abbott®, Abbott Park, 
North Chicago, Illinois, USA).
measurement of total oxidant status
Serum TOS was measured using a novel automated 
method developed by Erel (18). Oxidants present in the 
sample oxidize the ferrous ion-odianisidine complex to 
ferric ion. The oxidation reaction is enhanced by glycerol 
molecules, which are abundant in the reaction medium. 
The ferric ion generates a colored complex with Xylenol 
Orange in an acidic medium. Color intensity, which can 
be measured spectrophotometrically (V-530; Jasco®, To-
kyo, Japan), is related to the quantity of oxidant molecules 
present in the sample. The assay is calibrated with hydro-
gen peroxide and the results expressed in terms of micro-
molar hydrogen peroxide equivalents per liter (μmol 
H2O2 equivalent/L).
measurement of total antioxidant 
status
Serum TAS was measured using a novel automated 
method developed by Erel (19). In this method, hydroxyl 
radical, the most potent biological radical, is produced. 
In the assay, ferrous ion solution in reagent 1 is mixed 
with hydrogen peroxide present in reagent 2. Sequen-
tially- produced radicals, such as the brown-colored dia-
nisidinyl radicalcation produced by the hydroxyl radical, 
are also potent radicals. This method allows measuring 
the antioxidant effect of the sample against potent free-
radical reactions that are initiated by the hydroxyl radical. 
The assay has excellent precision values of more than 
97%. The results are expressed as μmol Trolox 
equivalent/L.
oxidative stress Index
The OSI was defined as the ratio of the TOS to TAS 
levels (18, 19). TAS levels were converted to μmol. The 
percentage of TOS level to TAS level was regarded as the 
oxidative stress index (OSI). The serum OSI value was 
calculated as follows:
OSI (AU) = [(TOS, μmol H2O2 equivalent/L)/(TAS, 
μmol Trolox equivalent/L)]×100. The results were ex-
pressed in Arbitrary Units.
statistical analysis
All statistical analyses were performed using SPSS for 
Windows version 17.0 (SPSS Inc., Chicago, IL, USA). 
Kolmogorov- Smirnov tests were used to test the normal-
ity of data distribution. The data were expressed as arith-
metic means and standard deviations. Independent sam-
ple T-test was respectively used in normally and 
non-normally distributed continuous variables between 
groups. Paired test was used to analyze changes within 
each group. Two-sided p value < 0.05 was considered sta-
tistically significant.
results
The demographic, clinical and laboratory data of all 
study participants are shown in Table 1; no significant 
differences between the two groups regarding to these 
data were noted. All oxidative stress markers (TAS, TOS, 
and OSI) were significantly different among the groups 
(p < 0.001 for all) (Table 2). Compared to the control 
group, the TOS and OSI values of the IBS patients were 
determined to be higher and the TAS values were lower.
dIscussIon
The main finding of the present study was that TOS 
values were higher and TAS values were lower in patients 
with IBS compared to control. In light of this information 
we can say there is an oxidative injury in the IBS although 
we cannot clear up whether it is a cause or a result.
Traditionally, IBS has been considered as a condition 
arising from brain-gut dysregulation and classified as one 
of the functional gastrointestinal disorders, hence its 
symptoms not explained by structural or biochemical ab-
normalities (4). Supports this fact IBS has been demon-
strated accompanied by depression, anxiety, fibromyalgia 
syndrome and gastric esophagial reflux disease in resent 
studies (20-26).
Epidemiological studies have been shown the increased 
oxidative stress in inflammatory, degenerative and endo-
crine diseases which affect tissues integrity and meta-
bolic rate of body. There were several studies demonstrat-
ing higher concentrations of oxidative stress products and 
antioxidants in the chronic inflammatory diseases of gas-
trointestinal tractus such as crohn disease, ulcerative coli-
tis and chronic hepatitis. Especially superoxide dismutase 
protein carbonyl content (POPs), DNA oxidation prod-
ucts [8-hydroxy-2’-deoxyguanosine (8-OHdG)], reactive 
oxygen intermediates (ROIs), lipid peroxidation products 
malonaldehyde (MDA) and 4-hydroxynonenal (HNE), 
catalase (CAT), glutathione peroxidase (GSH-Px), xan-
thine oxidase (XO), adenosine deaminase (AD) activities, 
and malondialdehyde (MDA) and nitric oxide (NO) were 
studied in these studies (27-31). However there is limited 
number of study evaluating oxidative stress products in 
IBS. Mete R. et al. (32) evaluated the plasma concentra-
tions of malondialdehyde (MDA) and nitric oxide (NO) 
and the plasma activities of oxidant and antioxidant en-
zymes (Superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GSH-Px), xanthine oxidase (XO), 
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adenosine deaminase (AD) activities) patients with IBS. 
Plasma XO and AD activities, lipid peroxidation product 
MDA and NO concentrations were significantly higher 
in IBS patients than in controls. The SOD, CAT, and 
GSH-Px activities in the serum of patients with IBS were 
significantly lower than that of controls. Oran et al. (33) 
demonstrated the presence of oxidative stress, a distur-
bance in prooxidant – antioxidant balance and increased 
inflammation in patients with IBS by showing the drop 
in paraoxonase and arylesterase activities accompanied 
with an increase in conjugated diene levels. Urinary redox 
potential had also been studied in depression, MDA and 
SOD in fibromyalgia, which are the other functional dis-
eases related with IBS (34-36). In our study, we evaluated 
the TAS and TOS values by Erel’s method which has high 
linearity, rapid, easy, stable, reliable, sensitive, inexpensive 
and fully automated and the results are highly reproduc-
ible (18, 19). We found TOS was increased and TAS was 
decreased in patients with IBS compared to the controls 
similar to previous studies that specific oxidative stress 
markers were evaluated in.
Additionally it was tired to explain the oxidative stress 
plays a role in the pathogenesis of IBS by evaluating the 
potential effects of antioxidants in previous experimental 
studies. Firstly Asadi-Shahmirzadi et al. (37) demonstra-
ted that the severity of stress-induced IBS was diminished 
by the Aloe vera/German chamomile mixture at all doses 
used but not dose-dependently, via inhibiting colonic 
MPO activity and improving oxidative stress status. Later 
Zhang et al. (38) evaluated the melatonin effects on gas-
tric residual rate, small intestine propulsion rate and re-
generation of gastric mucosa breaked down by noise 
stress. Melatonin is effective in reversing the gastrointes-
tinal motility disorder and gastric stress ulcer on noise 
stress induced rats by its antioxidant and neuroendocrine 
activity in the circadian organization that previously de-
monstrated (38). Lastly Garabadu et al. (39) demonstrated 
that Eugenol protected against restraint stress induced 
development of IBS-like gastrointestinal dysfunction th-
rough modulation of HPA-axis and brain monoaminergic 
pathways apart from its antioxidant effect. Similar studi-
es were performed in clinical subjects and demonstrated 
that antioxidants improves IBS symptoms. Kuiken SD et 
al. (40) argued a hypothesis that nitric oxide (NO) is in-
volved in maintaining visceral hypersensitivity in IBS and 
NO synthase inhibitor NG -monomethyl-L-arginine (L-
NMMA) can restore on rectal resting volume, rectal sen-
sitivity to distension and rectal compliance. Although 
L-NMMA did not alter rectal resting volume, rectal sen-
sitivity to distension and rectal compliance, significantly 
increased the threshold for discomfort/pain in IBS pati-
ents (40). Melatonin is one of the favorite therapeutic 
agent plays an important role in gastrointestinal physio-
logy and includes anxiolytic, anti-inflammatory and mo-
tility regulatory effects. In recent studies it was demons-
trated that its antioxidant effects plays a role to improve 
IBS symptoms (41, 42).
In conclusion our present study demonstrated that 
there is increased oxidative stress and decreased antioxi-
dant capacity in patient with IBS; therefore, we should 
consider that antioxidants might be beneficial in the sup-
portive treatment of IBS. The limitation of the present 
study is that the TAS, TOS and OSI values were not ex-
amined after the IBS treatment and they were not com-
pared to other inflammatory parameters and naturel an-
tioxidants such as albumin bilirubin and uric ascide. To 
support our results prospective and randomized con-
trolled trials are necessary.
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